Cargando…

Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs

Over the last decades, the increasing knowledge in the area of rheumatoid arthritis has progressively expanded the arsenal of available drugs, especially with the introduction of novel targeted therapies such as biological disease modifying antirheumatic drugs (DMARDs). In this situation, rheumatolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Favalli, Ennio Giulio, Bugatti, Serena, Biggioggero, Martina, Caporali, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009266/ https://www.ncbi.nlm.nih.gov/pubmed/24839607 http://dx.doi.org/10.1155/2014/831603

Ejemplares similares

Structural integrity versus radiographic progression in rheumatoid arthritis
por: Favalli, Ennio Giulio, et al.
Publicado: (2015)

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection
por: Biggioggero, Martina, et al.
Publicado: (2018)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
por: Crotti, Chiara, et al.
Publicado: (2018)

The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry
por: Becciolini, Andrea, et al.
Publicado: (2016)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
por: Crotti, Chiara, et al.
Publicado: (2017)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors
por: Biggioggero, Martina, et al.
Publicado: (2019)

Baricitinib for COVID-19: a suitable treatment?
por: Favalli, Ennio G, et al.
Publicado: (2020)

Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
por: Favalli, Ennio Giulio, et al.
Publicado: (2023)

Rheumatoid arthritis treatment: the earlier the better to prevent joint damage
por: Monti, Sara, et al.
Publicado: (2015)

COVID-19 infection and rheumatoid arthritis: Faraway, so close!
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

The Clinical Value of Autoantibodies in Rheumatoid Arthritis
por: Bugatti, Serena, et al.
Publicado: (2018)

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry
por: Favalli, Ennio Giulio, et al.
Publicado: (2018)

Damage progression in rheumatoid arthritis: the role of biologic agents
por: Favalli, Ennio Giulio
Publicado: (2012)

GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?
por: Favalli, Ennio Giulio, et al.
Publicado: (2020)

Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective
por: Bugatti, Serena, et al.
Publicado: (2012)

The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
por: Bobbio-Pallavicini, Francesca, et al.
Publicado: (2004)

Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
por: Favalli, Ennio Giulio, et al.
Publicado: (2022)

B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers
por: Bugatti, Serena, et al.
Publicado: (2014)

The Draining Lymph Node in Rheumatoid Arthritis: Current Concepts and Research Perspectives
por: Benaglio, Francesca, et al.
Publicado: (2015)

The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future
por: Biggioggero, Martina, et al.
Publicado: (2018)

Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis
por: Bugatti, Serena, et al.
Publicado: (2016)

Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry
por: Filippini, Matteo, et al.
Publicado: (2014)

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability
por: Becciolini, Andrea, et al.
Publicado: (2017)

Potential Short-Term Air Pollution Effects on Rheumatoid Arthritis Activity in Metropolitan Areas in the North of Italy: A Cross-Sectional Study
por: Ingegnoli, Francesca, et al.
Publicado: (2021)

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy
por: Degli Esposti, Luca, et al.
Publicado: (2016)

Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine
por: Spinelli, Francesca Romana, et al.
Publicado: (2022)

From Bench to Bedside in Rheumatoid Arthritis from the “2022 GISEA International Symposium”
por: Vitale, Antonio, et al.
Publicado: (2023)

Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis
por: Favalli, Ennio G.
Publicado: (2020)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
por: Bertoldi, Ilaria, et al.
Publicado: (2021)

Rheumatoid Arthritis from Easy to Complex Disease: From the “2022 GISEA International Symposium”
por: Perniola, Simone, et al.
Publicado: (2023)

Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors
por: Manzo, Antonio, et al.
Publicado: (2016)

COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country
por: Licciardi, Francesco, et al.
Publicado: (2020)

Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs
por: Bugatti, Serena, et al.
Publicado: (2012)

New Rheumatoid Arthritis Treatments for ‘Old’ Patients: Results of a Systematic Review
por: Caporali, Roberto, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nmfvpecltsouapniq8b0st39t7